课题基金 / 基金详情

HEMORRHAGE-INDUCED SUPPRESSION OF IMMUNE RESPONSE

HEMORRHAGE-INDUCED SUPPRESSION OF IMMUNE RESPONSE
出血引起的免疫反应抑制
批准号:
3295964
负责人:
YI-HAN CHANG
金额:
$27.91万
依托单位国家:
美国
项目类别:
财政年份:
1988
资助国家:
美国
项目状态:
已结题
起止时间:
1988-02-01 至 1995-01-31

项目摘要

项目成果

YI-HAN CHANG的其他基金

相似基金

相关文献

中文摘要
翻译
免疫反应减弱似乎是造成这种损害的原因 在出血和创伤后宿主防御中的作用我们找到了一个 出血后T细胞的大量功能异常。 最初的研究表明,B细胞的某些功能也是 不正常.出血性血清中存在的16000道尔顿的多肽是 分离,部分测序,并发现激活抑制性T细胞。 这些激活的抑制性T细胞负责大多数,如果不是全部, 观察到异常。长期目标是阐明 出血后导致宿主防御受损的事件 并评估抑制剂的潜在临床用途 细胞活化因子(SCAF),这是本建议的目的 研究目的是(1)进一步表征老化诱导的改变 在B细胞活性和抗体应答中的作用;(2)确定机制 SCAF在亚细胞和分子水平上的作用;(3)测试 我们的假设是出血后免疫抑制和 发展中的感染可以通过父母的干预来预防或逆转。 施用抗SCAF或抗SCAF受体抗体。 具体而言,我们建议(1)确定出血对血清 细菌抗原特异性抗体的水平和数量, 百分比以及抗原特异性脾血浆的活性 (2)确定出血对抗体应答的影响, 肺粘膜浆细胞;(3)评估可能的损伤诱导 通过确定抗体应答调节的改变 B细胞与辅助性T细胞、抑制性T细胞以及 出血后的独特型网络;(4)制备合成的和 重组SCAF、抗SCAF抗体和抗SCAF受体 抗体;(5)确定抗- SCAF或抗SCAF受体抗体对抑郁症的影响 (6)评估抗SCAF抗体可能的保护作用 或抗SCAF受体抗体对抗实验性肺炎, 小鼠;(7)确定SCAF在细胞, 亚细胞和分子水平,通过确定其对 介质的产生和释放,细胞质酶激活, 核鸟氨酸脱羧酶诱导和多胺生物合成。 从这些研究产生的结果应该导致更好的 了解宿主对感染的防御能力受损, 发生在出血和创伤后, 方法,如测量SCAF血液水平, 识别患有出血性、创伤性或热损伤的患者 他们感染的风险特别高。实验验证 出血后免疫抑制和倾向性 对于发展中的感染可以预防和/或逆转的父母 抗SCAF或抗SCAF受体抗体的施用应 为危重III期创伤的临床管理提供了新的方法 患者从本提案的角度看,常设委员会在以下方面的作用 调节正常的免疫反应和介导免疫抑制, 以及其在器官移植中的潜在临床用途 移植和治疗自身免疫性疾病, 系统性红斑狼疮(SLE)或1型糖尿病, 未来调查的重要领域。
英文摘要
A depressed immune response appears to be responsible for the impairment in host defense following hemorrhage and trauma. We have found a multitude of functional abnormalities in post-hemorrhage T cells. Initial studies showed that certain functions of B cells are also abnormal. A 16000 Dalton polypeptide present in hemorrhagic serum was isolated, partially sequenced, and found to activate suppressor T cells. These activated suppressor T cells are responsible for most, if not all, observed abnormalities. With the long term goal of elucidating the events that lead to the impairment of host defense following hemorrhage and trauma and to assess potential clinical usefulness of the suppressor cell activating factor (SCAF), it is the objective of this proposed investigation to (1) further characterize hemorrhage-induced alterations in B cell activities and antibody response; (2) ascertain the mechanisms of action of SCAF at the subcellular and molecular levels; and (3) test our hypothesis that post-hemorrhage immunodepression and propensity for developing infection can be prevented or reversed by parental administration of anti-SCAF or anti-SCAF-receptor antibodies. Specifically, we propose to (1) determine effects of hemorrhage on serum levels of bacterial antigen specific antibodies and the number, percentages, as well as activities of antigen specific splenic plasma cells; (2) determine the effects of hemorrhage on antibody response of pulmonary mucosal plasma cells; (3) assess possible hemorrhage-induced alteration in the regulation of antibody response by determining interactions of B cells with helper T cells, suppressor T cells, and the idiotype network following hemorrhage; (4) prepare synthetic and recombinant SCAF, anti-SCAF antibodies and anti-SCAF-receptor antibodies; (5) determine effects of parental administration of anti- SCAF or anti-SCAF-receptor antibodies on hemorrhage-induced depression of immune response; (6) assess possible protective effect of anti-SCAF or anti-SCAF-receptor antibodies against experimental pneumonia in the mouse; (7) ascertain mechanisms of action of SCAF at the cellular, subcellular and molecular levels by determining its effects on the generation and release of mediators, cytoplasmic enzyme activation, nuclear ornithine decarboxylase induction, and polyamine biosynthesis. Results generated from these studies should lead to a better understanding of the impairment of host defense against infections that occurs following hemorrhage and trauma as well as permit the development of methodologies, such as the measurement of SCAF blood levels, for identifying patients with hemorrhagic, traumatic, or thermal injuries who are at particularly high risk of infections. Experimental validation of our hypotheses that post-hemorrhage immunodepression and propensity for developing infections can be prevented and/or reversed by parental administration of anti-SCAF or anti-SCAF-receptor antibodies should provide new approaches for clinical management of critically III trauma patients. Looking beyond the present proposal, the role(s) of SCAF in regulating normal immune response and in mediating immune depressions in aging, as well as its potential clinical usefulness in organ transplantation and in the treatment of auto-immune disease such as systemic lupus erythematosus (SLE) or type 1 diabetes mellitus are important areas for future investigation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
HEMORRHAGE-INDUCED SUPPRESSION OF IMMUNE RESPONSE
HEMORRHAGE-INDUCED SUPPRESSION OF IMMUNE RESPONSE
CELLULAR MECHANISMS OF HEMORRHAGED-INDUCED SUPPRESSION
CELLULAR MECHANISMS OF HEMORRHAGED-INDUCED SUPPRESSION
海外基金